Author + information
- Received April 3, 2018
- Revision received June 6, 2018
- Accepted June 6, 2018
- Published online August 20, 2018.
- aDepartment of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands
- bDepartment of Electrophysiology, Alfried Krupp Krankenhaus, Essen, Germany
- cWitten/Herdecke University, Witten, Germany
- ↵∗Address for correspondence:
Dr. Fred Wittkampf, Department of Cardiology, University Medical Center Utrecht, Kloosterlaan 23, 3749AJ Lage Vuursche, the Netherlands.
Irreversible electroporation can be used as a nonthermal energy source to ablate tissue. Cardiac catheter ablation by irreversible electroporation may be a safe and effective alternative for thermal ablation techniques such as radiofrequency or cryoablation. Total applied current, not delivered power (watts), energy (joules), or voltage, is the parameter that most directly relates to the local voltage gradient that causes electroporation. Electroporation can be achieved with various modalities: direct current, alternating current, pulsed direct current, or any combination of these. Experimental cardiac and noncardiac studies have demonstrated tissue specificity with survival of arteries and nerves in large lesions. In addition, porcine data suggest that application inside a pulmonary vein does not lead to pulmonary vein stenosis and that the esophagus is remarkably insensitive to electroporation. Therefore, irreversible electroporation is a very promising technique for cardiac catheter ablation and especially for electrical pulmonary vein isolation.
Dr. Wittkampf is consultant for Abbott and St. Jude Medical; and is a coinventor of circular electroporation ablation and receives royalties from its commercial use. Dr. van Es is a coinventor of circular electroporation ablation and receives royalties from its commercial use. Dr. Neven is a consultant for Abbott.
All authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Clinical Electrophysiology author instructions page.
- Received April 3, 2018.
- Revision received June 6, 2018.
- Accepted June 6, 2018.
- 2018 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.